Scientists discovered “obelisks” described as a new biological “entity” in the human body. “It’s insane,” one researcher told Science Magazine.
Category: biotech/medical – Page 673
Consensus report of the 2021 National Cancer Institute neuroendocrine tumor clinical trials planning meeting
Abstract. Important progress has been made over the last decade in the classification, imaging, and treatment of neuroendocrine neoplasm (NENs), with several new agents approved for use. Although the treatment options available for patients with well-differentiated neuroendocrine tumors (NETs) have greatly expanded, the rapidly changing landscape has presented several unanswered questions about how best to optimize, sequence, and individualize therapy. Perhaps the most important development over the last decade has been the approval of 177 Lu-DOTATATE for treatment of gastroenteropancreatic-NETs, raising questions around optimal sequencing of peptide receptor radionuclide therapy (PRRT) relative to other therapeutic options, the role of re-treatment with PRRT, and whether PRRT can be further optimized through use of dosimetry among other approaches. The NET Task Force of the National Cancer Institute GI Steering Committee convened a clinical trial planning meeting in 2021 with multidisciplinary experts from academia, the federal government, industry, and patient advocates to develop NET clinical trials in the era of PRRT. Key clinical trial recommendations for development included 1) PRRT re-treatment, 2) PRRT and immunotherapy combinations, 3) PRRT and DNA damage repair inhibitor combinations, 4) treatment for liver-dominant disease, 5) treatment for PRRT-resistant disease, and 6) dosimetry-modified PRRT.
How Obesity Dismantles Our Mitochondria
How Obesity Dismantles the Powerhouse of the Cell: A new UC San Diego School of Medicine study in Nature Portfolio (Metabolism) sheds light on how obesity affects our mitochondria, the all-important energy-producing structures of our cells.
UC San Diego researchers found that when mice were fed a high-fat diet, mitochondria within their fat cells broke apart and were less able to burn fat, leading to weight gain. They also found they could reverse the effect by targeting a single gene, suggesting a new treatment strategy for obesity.
Promising New Therapy for a Hard-to-Treat Blood Cancer
Mutated stem cells known as leukemia stem cells (LSCs) initiate and fuel the development of acute myeloid leukemia (AML), an aggressive and usually fatal blood cancer.
Researchers at Albert Einstein College of Medicine describe a promising new strategy for treating and possibly curing acute myeloid leukemia by targeting leukem.
U of T researchers’ AI model designs proteins to deliver gene therapy
University of Toronto Engineering researchers’ AI model designs proteins to deliver gene therapy ➡️
Researchers at the University of Toronto used an artificial intelligence framework to redesign a crucial protein involved in the delivery of gene therapy.
The study, published in Nature Machine Intelligence, describes new work optimizing proteins to mitigate immune responses, thereby improving the efficacy of gene therapy and reducing side effects.
“Gene therapy holds immense promise, but the body’s pre-existing immune response to viral vectors greatly hampers its success. Our research zeroes in on hexons, a fundamental protein in adenovirus vectors, which – but for the immune problem – hold huge potential for gene therapy,” says Michael Garton, an assistant professor at the Institute of Biomedical Engineering in the Faculty of Applied Science & Engineering.
Scientists build high power cladding-pumped Raman fiber laser at 1.2 μm waveband
Laser sources operating at the 1.2 μm wavelength band have some unique applications in photodynamic therapy, biomedical diagnosis and oxygen sensing. Additionally, they can be adopted as pump sources for mid-infrared optical parametric generation as well as visible light generation by frequency doubling.
Laser generation at 1.2 μm waveband has been achieved with different solid-state lasers including semiconductor lasers, diamond Raman lasers, and fiber lasers. Among these three types, the fiber laser thanks to its simple structure, good beam quality, and operation flexibility, is a great choice for 1.2 μm waveband laser generation.
Researchers led by Prof. Pu Zhou at National University of Defense Technology (NUDT), China, are interested in a high power fiber laser at 1.2 μm waveband. Current high power fiber lasers are mostly ytterbium-doped fiber lasers at 1 μm waveband, and the maximum output at 1.2 μm waveband is limited at 10-watt level.